Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

0.3763
+0.02597.39%
Post-market: 0.3761-0.0002-0.05%19:30 EDT
Volume:128.46K
Turnover:47.28K
Market Cap:14.21M
PE:-0.86
High:0.3900
Open:0.3630
Low:0.3512
Close:0.3504
52wk High:1.98
52wk Low:0.2500
Shares:37.77M
Float Shares:25.85M
Volume Ratio:0.24
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4366
EPS(LYR):-0.4366
ROE:-2174.98%
ROA:-247.30%
PB:-9.11
PE(LYR):-0.86

Loading ...

NeuroSense files Form 3 for CTO Niva Russek-Blum initial beneficial ownership

Reuters
·
Mar 31

NeuroSense CEO Alon Ben-Noon files initial beneficial ownership statement

Reuters
·
Mar 30

NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks

Reuters
·
Mar 24

NeuroSense Therapeutics Director Cary J. Claiborne Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

NeuroSense Therapeutics Ltd. Director Roy Golan Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

NeuroSense Therapeutics Ltd. Director Mark Leuchtenberger Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

NeuroSense Therapeutics Ltd. files Form 3 initial beneficial ownership statement for General Manager Hagit Binder

Reuters
·
Mar 19

NeuroSense to Present PrimeC Phase 2b PARADIGM Data at AD/PD 2026 Conference

Reuters
·
Mar 18

Health Rounds: Blood test improves detection of endometriosis

Reuters
·
Mar 18

Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Assertio Therapeutics (ASRT) and LENSAR (LNSR)

TIPRANKS
·
Mar 17

NeuroSense Phase 2b PARADIGM trial links PrimeC to 36% slower ALS progression and 64% lower complication risk

Reuters
·
Mar 16

Jama Neurology Publishes Results From Paradigm Phase 2B Trial of Primec in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

THOMSON REUTERS
·
Mar 16

NeuroSense Therapeutics shareholders approve articles amendment to increase registered share capital

Reuters
·
Mar 11

Roth Capital Partners Initiates Neurosense Therapeutics at Buy

MT Newswires Live
·
Mar 10

NeuroSense initiated with a Buy at Roth Capital

TIPRANKS
·
Mar 10

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN) and Novo Nordisk (NVO)

TIPRANKS
·
Mar 10

NeuroSense reports additional long-term survival data from PARADIGM 2b trial

TIPRANKS
·
Feb 18

NeuroSense reports PrimeC cut ALS death risk 65% in Phase 2b trial

Reuters
·
Feb 18